Daily Endocrinology Research Analysis
Analyzed 43 papers and selected 3 impactful papers.
Summary
Analyzed 43 papers and selected 3 impactful articles.
Selected Articles
1. Epigenetic adaptation of beta cells across lifespan and disease.
Using cell-type-specific human methylomes, the authors show progressive age-related demethylation at regulatory elements of beta cell identity/function genes, with an opposite trend in alpha cells. In type 2 diabetes, beta cells exhibit further demethylation, suggesting an accelerated, ultimately failing compensatory epigenetic response to chronic insulin resistance.
Impact: This rigorous mechanistic human study reframes beta-cell aging as adaptive epigenetic remodeling that accelerates in T2D, offering a framework for biomarker discovery and therapeutic targeting of beta-cell resilience.
Clinical Implications: Identifying beta-cell DNAm signatures across aging and T2D could inform risk stratification, track therapeutic responses, and guide development of epigenetic or metabolic interventions to preserve beta-cell function.
Key Findings
- Progressive age-related demethylation at cis-regulatory elements of beta cell identity/function genes in healthy donors
- Alpha cells display a contrasting pattern with subtle age-related hypermethylation
- Type 2 diabetes beta cells show further demethylation, indicating an accelerated compensatory epigenetic response
Methodological Strengths
- Cell-type-specific methylome profiling from human donors
- Comparative analysis across endocrine cell types (beta vs alpha) linking epigenome to function
Limitations
- Cross-sectional design limits causal inference about the drivers of methylation changes
- Lack of interventional perturbation to directly link DNAm remodeling to beta-cell functional outcomes
Future Directions: Integrate longitudinal donor data, functional perturbations, and single-cell multi-omics to causally link specific epigenetic modifications to beta-cell survival and function under metabolic stress.
Although the prevalence of type 2 diabetes (T2D) increases with age, most adults maintain normoglycaemia despite rising insulin resistance owing to the adaptive capacity of pancreatic beta cells to meet increased metabolic demand. However, persistent insulin resistance can lead to beta cell dysfunction and T2D onset. Here we show the mapping of genome-wide DNA methylation (DNAm) patterns and the epigenomic basis of beta cell adaptations by leveraging cell-type-specific methylome data from the Human Pancreas Analysis Program. In healthy donors, we identify progressive age-related demethylation enriched in cis-regulatory elements at beta cell identity and function genes. By contrast, alpha cells show the opposite trajectory, with subtle, age-related hypermethylation. In T2D beta cells, but not alpha cells, we observed further demethylation compared to healthy controls, underscoring a unique capacity of beta cells to respond to changes in metabolic demand. Together, our findings suggest that DNAm remodelling in healthy beta cells reflects a long-term adaptation to metabolic demand, which, in T2D, is accelerated as part of a compensatory response that ultimately fails under sustained insulin resistance.
2. Genome-wide CRISPR screen identifies TAF1C as an epigenetic determinant of lipid deposition via ACSL4-dependent ferroptosis in MASLD.
A genome-wide CRISPR screen and chromatin profiling identify TAF1C as a central epigenetic regulator of hepatic steatosis. TAF1C reprograms enhancer landscapes via SETD1A, upregulates ACSL4, promotes lipid synthesis, and induces ferroptosis; genetic perturbation and a TAF1 inhibitor reduce steatosis in vitro and in vivo.
Impact: This study provides a genetically and mechanistically validated therapeutic target (TAF1C) for MASLD and suggests a repurposing path for TAF1 inhibitors, addressing a major unmet need in metabolic liver disease.
Clinical Implications: Targeting TAF1C-driven enhancer remodeling and ACSL4-dependent ferroptosis could yield first-in-class therapies for MASLD; safety and selectivity of epigenetic modulation will be critical for translation.
Key Findings
- Genome-wide CRISPR screening in steatotic hepatocytes identifies TAF1C as a driver of hepatic steatosis
- TAF1 inhibitor (CeMMEC13) and TAF1C knockdown reduce lipid accumulation in vitro and in vivo
- TAF1C interacts with SETD1A to modulate H3K4me3/H3K27me3 and H3K27ac, upregulating lipid metabolism genes including ACSL4 and inducing ferroptosis
Methodological Strengths
- Unbiased genome-wide CRISPR/Cas9 functional screening
- Multi-omics validation (ATAC-seq, chromatin mark profiling) with in vitro and in vivo perturbation
Limitations
- Preclinical models; absence of human interventional or clinical outcome data
- Selectivity of TAF1C targeting and potential off-target effects of epigenetic drugs require assessment
Future Directions: Assess TAF1C inhibition in human liver organoids and early-phase clinical studies; develop selective TAF1C modulators and biomarkers (e.g., enhancer signatures, ACSL4 activity) to guide patient selection.
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent liver disease, garnering considerable attention. Currently, there are no satisfactory drugs available clinically due to the lack of efficacious therapeutic targets. APPROACH AND RESULTS: By using genome-wide CRISPR/Cas9 screening and ATAC-seq in steatotic hepatocytes, we systematically identify TAF1C as crucial epigenetic determinant of MASLD. CeMMEC13, an inhibitor of TAF1, significantly alleviates hepatic steatosis. Knockdown of TAF1C, significantly ameliorates lipid accumulation in steatotic hepatocytes both in vitro and in vivo. TAF1C expression was gradually upregulated in liver tissues during MASLD progression. Overexpressing TAF1C induces excessive lipid deposition in steatotic hepatocytes. Mechanistically, TAF1C directly interacts with the H3K4 methyltransferase SETD1A to reprogram epigenetic landscape by administrating H3K4me3 and H3K27me3 marks. TAF1C regulates H3K27ac deposition, thereby modulating the activities of enhancers and super-enhancers, which ultimately upregulates the expression of genes associated with lipid metabolism. By epigenetic reprogramming, TAF1C increases ACSL4 expression, accelerating lipid synthesis and inducing ferroptosis. CONCLUSIONS: Our research identifies that TAF1C drives liver steatosis through epigenetic reprogramming, positioning it as a therapeutic target for MASLD.
3. Causal relationship between epigenetic markers and type 2 diabetes in West African populations: a Mendelian randomisation analysis.
Leveraging MR in 879 Ghanaian and 332 Nigerian participants, the study pinpoints two CpG sites with evidence of causal effects on type 2 diabetes risk. Findings support population-specific epigenetic biomarkers and targets, advancing precision endocrinology in underrepresented high-burden groups.
Impact: This study advances causal inference for epigenetic markers of T2D in West African populations, addressing a major diversity gap and informing biomarker and therapeutic target prioritization.
Clinical Implications: Causal CpG markers can guide early detection and risk stratification in West African populations and inform target selection for interventions modifying epigenetic pathways.
Key Findings
- Mendelian randomisation identified two CpG sites with causal effects on type 2 diabetes in West African cohorts
- Study combined EWAS with longitudinal data in 879 Ghanaian and 332 Nigerian individuals not on glucose-lowering therapy
- Results support prioritisation of epigenetic biomarkers and targets specific to underrepresented African populations
Methodological Strengths
- Use of Mendelian randomisation to strengthen causal inference for DNA methylation sites
- Inclusion of two independent West African cohorts with harmonised epigenome profiling
Limitations
- Peripheral blood methylation may not reflect disease-relevant tissues (e.g., pancreatic islets, liver, adipose)
- Moderate sample size and limited number of causal CpGs identified warrant broader replication
Future Directions: Replicate findings in larger African and non-African cohorts, integrate tissue-specific methylomes, and test whether modifying implicated pathways alters glycaemic trajectories.
AIMS/HYPOTHESIS: Evidence for a causal role of DNA methylation sites (CpGs) in type 2 diabetes and glycaemic traits is limited due to the cross-sectional nature of many epigenome-wide association studies (EWAS). In addition, epigenetic studies in West African populations are particularly sparse, despite the high and rising burden of type 2 diabetes in these populations. Hence, we aimed to identify CpGs causally associated with type 2 diabetes among West Africans by leveraging Mendelian randomisation (MR) analysis and longitudinal data. METHODS: We used the Illumina EPIC DNA methylation array to profile the methylation of DNA extracted from white blood cells collected from 879 Ghanaian individuals (the Research on Obesity and Diabetes among African Migrants [RODAM] study) and 332 Nigerian individuals (the Africa America Diabetes Mellitus [AADM] study) who were not on glucose-lowering medication. We carried forwards CpGs identified in EWAS for type 2 diabetes and meta-analysed EWAS for HbA RESULTS: We identified 28 CpGs associated with type 2 diabetes, 26 with HbA CONCLUSIONS/INTERPRETATION: Our study identified two epigenetic markers as likely to be causal for type 2 diabetes in West African populations. In addition to enhancing our understanding of disease mechanisms, these CpGs with evidence of causal associations could be prioritised as potential biomarkers for early detection of disease or as drug development targets.